Monte Rosa Therapeutics, Inc. (GLUE)
Automate Your Wheel Strategy on GLUE
With Tiblio's Option Bot, you can configure your own wheel strategy including GLUE - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol GLUE
- Rev/Share 1.9414
- Book/Share 3.3495
- PB 1.2629
- Debt/Equity 0.1521
- CurrentRatio 5.6113
- ROIC -0.0041
- MktCap 260186454.0
- FreeCF/Share 0.371
- PFCF 8.5369
- PE 56.4747
- Debt/Assets 0.1065
- DivYield 0
- ROE 0.0265
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 1
- DCF Score 5
- P/B Score 3
- D/E Score 3
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Downgrade | GLUE | Wells Fargo | Overweight | Equal Weight | $14 | $11 | Dec. 19, 2024 |
News
Monte Rosa Therapeutics (GLUE) Tops Q1 Earnings and Revenue Estimates
Published: May 08, 2025 by: Zacks Investment Research
Sentiment: Positive
Monte Rosa Therapeutics (GLUE) came out with quarterly earnings of $0.57 per share, beating the Zacks Consensus Estimate of a loss of $0.24 per share. This compares to loss of $0.53 per share a year ago.
Read More
Monte Rosa Therapeutics Presents Preclinical Data at American Association for Cancer Research (AACR) Annual Meeting 2025 on the Potential of its CDK2-directed Molecular Glue Degrader to Treat HR-positive/HER2-negative Breast Cancer
Published: April 28, 2025 by: GlobeNewsWire
Sentiment: Neutral
CDK2 molecular glue degrader (MGD) in combination with CDK4/6 inhibition and anti-estrogen therapy achieved superior tumor regression in vivo compared to standard of care CDK4/6 inhibition and anti-estrogen therapy CDK2 MGD delayed resistance to CDK4/6 inhibition in vitro and displayed superior selectivity versus clinical-stage CDK2 inhibitors BOSTON, April 28, 2025 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced the company will present preclinical data on the potential of its highly selective cyclin-dependent kinase 2 (CDK2)-directed molecular glue degrader, MRT-51443, to treat HR-positive/HER2-negative breast cancer at the …
Read More
Monte Rosa Therapeutics, Inc. (GLUE) Q4 2024 Earnings Call Transcript
Published: March 20, 2025 by: Seeking Alpha
Sentiment: Neutral
Monte Rosa Therapeutics, Inc. (NASDAQ:GLUE ) Q4 2024 Results Conference Call March 20, 2025 8:00 AM ET Company Participants Andrew Funderburk - Senior Vice President, Investor Relations and Strategic Finance Markus Warmuth - Chief Executive Officer Filip Janku - Chief Medical Officer Sharon Townson - Chief Scientific Officer Phil Nickson - Chief Business and Legal Officer Conference Call Participants Kelly Shi - Jefferies Edward Tenthoff - Piper Sandler Mark Fromm - TD Cowen Robert Driscoll - Wedbush Michael Schmidt - Guggenheim Eric Joseph - JPMorgan Operator Greetings, and welcome to Monte Rosa Therapeutics Conference Call to discuss the company's pipeline …
Read More
Monte Rosa Therapeutics (GLUE) Q4 Earnings and Revenues Top Estimates
Published: March 20, 2025 by: Zacks Investment Research
Sentiment: Positive
Monte Rosa Therapeutics (GLUE) came out with quarterly earnings of $0.23 per share, beating the Zacks Consensus Estimate of a loss of $0.37 per share. This compares to loss of $0.58 per share a year ago.
Read More
Monte Rosa Therapeutics Announces Fourth Quarter 2024 Financial Results and Provides Corporate Update Including New Clinical Results from MRT-6160 and MRT-2359 Programs
Published: March 20, 2025 by: GlobeNewsWire
Sentiment: Neutral
Results of the MRT-6160 Phase 1 SAD/MAD study demonstrate deep VAV1 degradation of greater than 90%, significant T and B cell functional inhibition as well as significant inhibition of cytokine release from T and B cells following ex-vivo stimulation, and favorable safety/tolerability profile; data support clear path to Phase 2 studies and broad potential applications in immune-mediated diseases Phase 1/2 study of MRT-2359 demonstrates encouraging signals of clinical response in castration-resistant prostate cancer (CRPC) patients resistant to AR therapy, including confirmed RECIST response; CRPC cohort will be focus moving forward with additional Phase 1/2 results expected in H2 2025; deprioritizing …
Read More
3 Top Cancer Biotechs to Keep An Eye On in 2025
Published: March 07, 2025 by: Zacks Investment Research
Sentiment: Neutral
If the cancer space appeals to you, it's time to consider stocks like Novartis, Exact Sciences and Monte Rosa.
Read More
Monte Rosa Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference
Published: February 24, 2025 by: GlobeNewsWire
Sentiment: Neutral
BOSTON, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines, today announced that Markus Warmuth, M.D., Chief Executive Officer, will present at the TD Cowen 45th Annual Health Care Conference on Monday, March 3, 2025, at 2:30 p.m.
Read More
Bullish On Monte Rosa Therapeutics' 'Undruggable' Targets With QuEEN
Published: February 16, 2025 by: Seeking Alpha
Sentiment: Positive
One of Monte Rosa Therapeutics' main differentiating factors is its proprietary QuEEN platform to design new molecular glue degraders. This process also leverages AI. They now have two important partnerships with Roche and Novartis, which I think validate its technology to some extent, but have also given it non-dilutive funding. Currently, its pipeline has MRT‑2359, MRT‑6160, and MRT‑8102, with key data expected in 2025.
Read More
About Monte Rosa Therapeutics, Inc. (GLUE)
- IPO Date 2021-06-24
- Website https://www.monterosatx.com
- Industry Biotechnology
- CEO Dr. Markus Warmuth M.D.
- Employees 142